Is a 6-month Treatment for Isoniazid-resistant Tuberculosis Effective?
https://doi.org/10.21292/2075-1230-2022-100-2-13-17
Abstract
The objective: to compare treatment efficacy and relapse rates in patients with isoniazid-resistant tuberculosis treated with 9- and 6-month courses of chemotherapy.
Subjects and Methods. A retrospective cohort study was conducted. The period from 2010 to 2015 was evaluated. The cases of tuberculosis registered on the territory of Arkhangelsk Region were studied. In 2010-2013, all patients with isoniazid-resistant tuberculosis (n = 130) in the region received a 9-month course of treatment. From 2014 to 2015, the duration of treatment for isoniazid-resistant tuberculosis in the region was reduced from 9 to 6 months. The patients (n = 54) received short-course treatment: aminoglycoside or polypeptide (2 months), rifampicin, pyrazinamide, fluoroquinolone, and ethambutol.
There was no statistically significant difference in treatment outcomes of isoniazid-resistant tuberculosis between two regimens: The outcome of effective treatment made 76.2% for the 9-month regimen and 74.1% for the 6-month regimen. The relapse rate per 100 person-years was 0.7 (95% CI 0.1-1.9) for the 9-month regimen and 1.9 (95% CI 0.2-6.7) for the 6-month regimen. This study confirmed the need to decrease the duration of treatment for isoniazid-resistant tuberculosis to 6 months.
About the Authors
A. I. Kulizhskaya
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Anastasiya I. Kulizhskaya - Head of and Statistics and Reporting Unit, Statistician Physician.
28, Novgorodsky Ave., Arkhangelsk, 163000
T. I. Gurieva
Northern State Medical University
Russian Federation
Russian Federation
Tatiana I. Gurieva - Resident Physician of the 2nd Year of Training in Phthisiology.
51, Troitsky Ave., Arkhangelsk, 163000
E. I. Nikishova
Northern State Medical University
Russian Federation
Russian Federation
Elena I. Nikishova - Professor of Phthisiology Department.
51, Troitsky Ave., Arkhangelsk, 163000
P. I. Eliseev
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Platon I. Eliseev - Physician of Clinical Diagnostic Laboratory.
28, Novgorodsky Ave., Arkhangelsk, 163000
D. V. Perkhin
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Dmitriy V. Perkhin - Head Physician.
28, Novgorodsky Ave., Arkhangelsk, 163000. Phone: +7 (8182) 68-38-91
А. O. Maryandyshev
Northern State Medical University; Northern (Arctic) Federal University Named after M.V. Lomonosov
Russian Federation
Russian Federation
Andrey O. Maryandyshev - Correspondent Member of RAMS, Professor, Head of Phthisiopulmonology Department.
51, Troitsky Ave., Arkhangelsk, 163000
References
1. Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults. ICD 10: A15 - A19. Revised in 2020. Moscow, 2020, pp. 121.
2. Edict Russia no. 951 by RF MoH as of December 29, 2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics Treatment. (In Russ.)
3. Gegia M., Winters N., Benedetti A. et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect. Dis., 2017, vol. 17, no. 2, pp. 223 -234.
4. GenoType MTBDRplus and GenoType MTBDRsl. Instructions for use. Hain Lifescience, 2008, Available at: http://www.hain-lifescience.de/en/technologies/dnastrip.html.
5. Global tuberculosis report 2017. Geneva, World Health Organization; 2017. pp. 262. Available at: https://www.who.int/tb/publications/global_report/archive/en/
6. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2020. pp. 146. Available at: https://www.who.int/publications/i/item/9789240007048.
7. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva, World Health Organization, 2018. pp. 45. Available at: https://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/
Review
For citations:
Kulizhskaya A.I., Gurieva T.I., Nikishova E.I., Eliseev P.I., Perkhin D.V., Maryandyshev А.O. Is a 6-month Treatment for Isoniazid-resistant Tuberculosis Effective? Tuberculosis and Lung Diseases. 2022;100(2):13-17. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-2-13-17
Views:
1431
Email this article 